Ceftriaxone was a third-generation cephalosporin antibacterial drug that was used to manage a wide variety of bacterial infections. It was given mainly through intravenous or intramuscular injection because it was not adequately absorbed when taken orally. The drug showed activity against a broad range of Gram-positive and Gram-negative bacteria. It was used for infections involving the respiratory tract, urinary tract, abdomen, bloodstream, skin and soft tissues, bones, and joints. It was also used for certain sexually transmitted infections and serious bacterial infections such as meningitis when the causative organisms were susceptible.
BRAND NAMES
Ceftriaxone was available under different brand names depending on the country, manufacturer, and formulation. Some commonly recognized trade names included Rocephin, Monocef, Cefaxone, Ceftriax, and products marketed simply as Ceftriaxone. The specific brand and available dosage forms varied between markets.
MECHANISM OF ACTION
Ceftriaxone acted by disrupting the formation of the bacterial cell wall. After reaching the bacterial target, it bound to specific enzymes known as penicillin-binding proteins (PBPs). These proteins participated in the final stages of peptidoglycan synthesis and cross-linking, which were essential for maintaining cell-wall strength. Inhibition of these enzymes weakened the bacterial cell wall, particularly in actively growing organisms, and eventually resulted in cell rupture and death. The antibacterial effect of ceftriaxone was therefore considered bactericidal.
PHARMACODYNAMICS
Ceftriaxone exerted its antibacterial effect primarily by maintaining drug concentrations above the minimum inhibitory concentration (MIC) for sufficient periods. It was active against a broad range of susceptible Gram-positive and Gram-negative bacteria, while its stability against many β-lactamases supported activity against certain β-lactamase-producing organisms. Resistance could occur through β-lactamase production, altered penicillin-binding proteins, reduced drug penetration, or other bacterial mechanisms. Ceftriaxone achieved therapeutic concentrations in various tissues and fluids and penetrated the cerebrospinal fluid during meningeal inflammation. Its relatively long elimination half-life supported once-daily administration in many infections, although dosing depended on infection severity, organism susceptibility, and patient-specific factors.
ADMINISTRATION
Ceftriaxone was administered through intravenous (IV) injection, intravenous infusion, or deep intramuscular (IM) injection. For IV use, the prepared solution was administered slowly or by infusion, whereas IM administration was given into a suitable large muscle. The selected route and duration of treatment depended on the type and severity of the infection, the patient’s age, body weight, and clinical condition.
DOSAGE AND STRENGTH
The dose of ceftriaxone sodium was determined according to the nature and severity of the infection, the patient’s age and body weight, and the response to treatment. In adults, doses commonly ranged from 1 to 2 g once daily, while higher doses could be used for severe infections when considered necessary. In children, the dose was generally calculated based on body weight. Ceftriaxone sodium was available as a powder for injection in different strengths, including 250 mg, 500 mg, 1 g, and 2 g.
DRUG INTERACTIONS
Ceftriaxone had clinically important interactions with certain medicines and intravenous solutions. Particular care was required when ceftriaxone was administered with calcium-containing IV solutions, especially in neonates, because ceftriaxone-calcium precipitates could form. Concomitant treatment with medicines that could affect renal function required suitable monitoring. Ceftriaxone sodium could also affect the results of some laboratory investigations, including certain glucose and coagulation tests.
FOOD INTERACTIONS
Ceftriaxone did not have a significant direct interaction with food because it was administered by injection rather than orally. Food therefore did not influence its absorption in the manner seen with orally administered medicines. Patients could generally continue their normal diet unless dietary restrictions were required because of their underlying medical condition or other treatment considerations.
CONTRAINDICATIONS
Ceftriaxone was not used in patients with known allergy to ceftriaxone, cephalosporins, or other β-lactam antibiotics. It was also contraindicated in hyperbilirubinemic neonates and in neonates requiring intravenous calcium-containing solutions because of the risk of bilirubin displacement and ceftriaxone-calcium precipitation.
SIDE EFFECTS
Ceftriaxone commonly caused diarrhea, nausea, vomiting, skin rash, itching, and injection-site discomfort. Changes in liver enzymes and blood-cell counts were also reported. Less common reactions included biliary sludge, antibiotic-associated colitis, and hypersensitivity, while severe allergic or skin reactions and neurological effects occurred rarely.
OVER DOSE
Excessive ceftriaxone exposure could produce neurological symptoms, particularly in patients with reduced renal function. Confusion, encephalopathy, abnormal movements, and seizures were reported in severe cases. Treatment was mainly supportive and involved stopping the drug and managing the symptoms, as no specific antidote was available.
TOXICITY
Ceftriaxone generally showed low toxicity at therapeutic doses. Toxic effects were more likely with excessive exposure or impaired renal or hepatic function and included gastrointestinal, hematological, hepatic, biliary, and allergic reactions. Rarely, prolonged or excessive exposure was associated with neurological toxicity or superinfection.
